NO317058B1 - Rapamycinderivater, fremgangsmate for fremstilling derav, farmasoytisk preparat omfattende et slikt derivat, kit omfattende et preparat samt anvendelse av derivatene - Google Patents

Rapamycinderivater, fremgangsmate for fremstilling derav, farmasoytisk preparat omfattende et slikt derivat, kit omfattende et preparat samt anvendelse av derivatene Download PDF

Info

Publication number: NO317058B1
Authority: NO; Norway
Prior art keywords: formula; compound; rapamycin; alkyl; preparation
Prior art date: 1995-06-09

Application number

NO19975432A

Other languages

English (en)

Norwegian (no)

Other versions

NO975432D0 (no

NO975432L (no

Inventor

Sylvain Cottens

Richard Sedrani

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-09

Filing date

1997-11-26

Publication date

2004-08-02

1995-06-09 Priority claimed from GBGB9511704.0A external-priority patent/GB9511704D0/en

1995-07-06 Priority claimed from GBGB9513754.3A external-priority patent/GB9513754D0/en

1997-11-26 Application filed by Novartis Ag filed Critical Novartis Ag

1997-11-26 Publication of NO975432D0 publication Critical patent/NO975432D0/no

1997-11-26 Publication of NO975432L publication Critical patent/NO975432L/no

2004-08-02 Publication of NO317058B1 publication Critical patent/NO317058B1/no

Links

238000000034 method Methods 0.000 title claims description 30
238000002360 preparation method Methods 0.000 title claims description 8
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title description 19
239000008194 pharmaceutical composition Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 108
229960002930 sirolimus Drugs 0.000 claims description 37
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
239000003814 drug Substances 0.000 claims description 16
125000000217 alkyl group Chemical group 0.000 claims description 15
229940079593 drug Drugs 0.000 claims description 14
239000000825 pharmaceutical preparation Substances 0.000 claims description 12
229910052739 hydrogen Inorganic materials 0.000 claims description 8
230000001506 immunosuppresive effect Effects 0.000 claims description 8
125000000304 alkynyl group Chemical group 0.000 claims description 7
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 claims description 6
208000023275 Autoimmune disease Diseases 0.000 claims description 5
206010052779 Transplant rejections Diseases 0.000 claims description 5
208000006673 asthma Diseases 0.000 claims description 5
239000003018 immunosuppressive agent Substances 0.000 claims description 5
125000006239 protecting group Chemical group 0.000 claims description 5
206010061218 Inflammation Diseases 0.000 claims description 4
230000001684 chronic effect Effects 0.000 claims description 4
230000004054 inflammatory process Effects 0.000 claims description 4
210000000056 organ Anatomy 0.000 claims description 4
239000008177 pharmaceutical agent Substances 0.000 claims description 4
QFMKPDZCOKCBAQ-NFCVMBANSA-N sar943-nxa Chemical group C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)CC1 QFMKPDZCOKCBAQ-NFCVMBANSA-N 0.000 claims description 4
230000001154 acute effect Effects 0.000 claims description 3
230000002924 anti-infective effect Effects 0.000 claims description 3
239000002260 anti-inflammatory agent Substances 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
229940125721 immunosuppressive agent Drugs 0.000 claims description 3
208000037803 restenosis Diseases 0.000 claims description 3
206010062016 Immunosuppression Diseases 0.000 claims description 2
208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
238000006894 reductive elimination reaction Methods 0.000 claims description 2
238000011916 stereoselective reduction Methods 0.000 claims description 2
229940124599 anti-inflammatory drug Drugs 0.000 claims 1
229940124622 immune-modulator drug Drugs 0.000 claims 1
239000002955 immunomodulating agent Substances 0.000 claims 1
238000004806 packaging method and process Methods 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
230000009467 reduction Effects 0.000 description 26
238000006722 reduction reaction Methods 0.000 description 26
239000000243 solution Substances 0.000 description 25
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 23
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
239000000203 mixture Substances 0.000 description 21
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
210000004027 cell Anatomy 0.000 description 17
238000012360 testing method Methods 0.000 description 16
230000035407 negative regulation of cell proliferation Effects 0.000 description 15
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 15
241000700159 Rattus Species 0.000 description 14
241001465754 Metazoa Species 0.000 description 13
-1 amide esters Chemical class 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000010410 layer Substances 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
230000009466 transformation Effects 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
210000003734 kidney Anatomy 0.000 description 9
230000002265 prevention Effects 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
238000005481 NMR spectroscopy Methods 0.000 description 8
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 8
230000027455 binding Effects 0.000 description 8
229920006395 saturated elastomer Polymers 0.000 description 8
235000017557 sodium bicarbonate Nutrition 0.000 description 8
229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
239000000126 substance Substances 0.000 description 8
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 8
108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 7
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
206010003246 arthritis Diseases 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
239000011159 matrix material Substances 0.000 description 7
230000036457 multidrug resistance Effects 0.000 description 7
238000000844 transformation Methods 0.000 description 7
238000002054 transplantation Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
101150041968 CDC13 gene Proteins 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000004440 column chromatography Methods 0.000 description 5
150000004678 hydrides Chemical class 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
230000010412 perfusion Effects 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
239000007787 solid Substances 0.000 description 5
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
150000004820 halides Chemical class 0.000 description 4
229940100601 interleukin-6 Drugs 0.000 description 4
150000002576 ketones Chemical class 0.000 description 4
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
244000052769 pathogen Species 0.000 description 4
239000012071 phase Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
210000004989 spleen cell Anatomy 0.000 description 4
239000007858 starting material Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000012085 test solution Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
108010036949 Cyclosporine Proteins 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
201000002491 encephalomyelitis Diseases 0.000 description 3
210000000548 hind-foot Anatomy 0.000 description 3
125000005016 hydroxyalkynyl group Chemical group 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000004530 micro-emulsion Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 3
238000005406 washing Methods 0.000 description 3
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
229930105110 Cyclosporin A Natural products 0.000 description 2
208000009329 Graft vs Host Disease Diseases 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
241000589248 Legionella Species 0.000 description 2
208000007764 Legionnaires' Disease Diseases 0.000 description 2
LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000003872 anastomosis Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000843 anti-fungal effect Effects 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000012267 brine Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
229960001338 colchicine Drugs 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
239000012043 crude product Substances 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
208000024908 graft versus host disease Diseases 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
229960003444 immunosuppressant agent Drugs 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
210000005240 left ventricle Anatomy 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
239000003120 macrolide antibiotic agent Substances 0.000 description 2
238000002595 magnetic resonance imaging Methods 0.000 description 2
229910052987 metal hydride Inorganic materials 0.000 description 2
150000004681 metal hydrides Chemical class 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
238000013059 nephrectomy Methods 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
WLPYSOCRPHTIDZ-UHFFFAOYSA-N pent-2-yn-1-ol Chemical compound CCC#CCO WLPYSOCRPHTIDZ-UHFFFAOYSA-N 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
235000009518 sodium iodide Nutrition 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
LALRXNPLTWZJIJ-UHFFFAOYSA-N triethylborane Chemical compound CCB(CC)CC LALRXNPLTWZJIJ-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
WJUKOGPNGRUXMG-UHFFFAOYSA-N 1,2-dibromo-1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)(Br)C(Cl)(Cl)Br WJUKOGPNGRUXMG-UHFFFAOYSA-N 0.000 description 1
GBBZLMLLFVFKJM-UHFFFAOYSA-N 1,2-diiodoethane Chemical compound ICCI GBBZLMLLFVFKJM-UHFFFAOYSA-N 0.000 description 1
CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
238000011749 CBA mouse Methods 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
108010036941 Cyclosporins Proteins 0.000 description 1
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
208000003556 Dry Eye Syndromes Diseases 0.000 description 1
206010013774 Dry eye Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
101100402621 Homo sapiens MSANTD4 gene Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
208000004883 Lipoid Nephrosis Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
101710155214 Macrophage infectivity potentiator Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010061269 Malignant peritoneal neoplasm Diseases 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
102100031642 Myb/SANT-like DNA-binding domain-containing protein 4 Human genes 0.000 description 1
241000187480 Mycobacterium smegmatis Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
241000588650 Neisseria meningitidis Species 0.000 description 1
208000034827 Neointima Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
101710114693 Outer membrane protein MIP Proteins 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
241000223960 Plasmodium falciparum Species 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
241000606651 Rickettsiales Species 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
102100027208 T-cell antigen CD7 Human genes 0.000 description 1
102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000005103 alkyl silyl group Chemical group 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000001675 anti-mdr Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
229910000085 borane Inorganic materials 0.000 description 1
PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
229950010231 brequinar Drugs 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000007978 cacodylate buffer Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
JOHCVVJGGSABQY-UHFFFAOYSA-N carbon tetraiodide Chemical compound IC(I)(I)I JOHCVVJGGSABQY-UHFFFAOYSA-N 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
ZDQWVKDDJDIVAL-UHFFFAOYSA-N catecholborane Chemical compound C1=CC=C2O[B]OC2=C1 ZDQWVKDDJDIVAL-UHFFFAOYSA-N 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
238000011254 conventional chemotherapy Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
LTYZGLKKXZXSEC-UHFFFAOYSA-N copper dihydride Chemical class [CuH2] LTYZGLKKXZXSEC-UHFFFAOYSA-N 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
108010019249 cyclosporin G Proteins 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
208000030172 endocrine system disease Diseases 0.000 description 1
CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 1
ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
238000003304 gavage Methods 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
150000007857 hydrazones Chemical class 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
230000005917 in vivo anti-tumor Effects 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229960000681 leflunomide Drugs 0.000 description 1
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
235000020778 linoleic acid Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000009061 membrane transport Effects 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
VKTOBGBZBCELGC-UHFFFAOYSA-M methyl(triphenoxy)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1O[P+](OC=1C=CC=CC=1)(C)OC1=CC=CC=C1 VKTOBGBZBCELGC-UHFFFAOYSA-M 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
229950000844 mizoribine Drugs 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
229960004866 mycophenolate mofetil Drugs 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
150000002940 palladium Chemical class 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
201000002524 peritoneal carcinoma Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000010992 reflux Methods 0.000 description 1
208000016691 refractory malignant neoplasm Diseases 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000010948 rhodium Substances 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
150000003342 selenium Chemical class 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
150000004756 silanes Chemical class 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Inorganic materials [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
235000011006 sodium potassium tartrate Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
238000010998 test method Methods 0.000 description 1
DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
125000005106 triarylsilyl group Chemical group 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
SCHZCUMIENIQMY-UHFFFAOYSA-N tris(trimethylsilyl)silicon Chemical compound C[Si](C)(C)[Si]([Si](C)(C)C)[Si](C)(C)C SCHZCUMIENIQMY-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000000304 virulence factor Substances 0.000 description 1
230000007923 virulence factor Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000012991 xanthate Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO19975432A 1995-06-09 1997-11-26 Rapamycinderivater, fremgangsmate for fremstilling derav, farmasoytisk preparat omfattende et slikt derivat, kit omfattende et preparat samt anvendelse av derivatene NO317058B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9511704.0A GB9511704D0 (en)	1995-06-09	1995-06-09	Organic compounds
GBGB9513754.3A GB9513754D0 (en)	1995-07-06	1995-07-06	Organic compounds
PCT/EP1996/002441 WO1996041807A1 (en)	1995-06-09	1996-06-05	Rapamycin derivatives

Publications (3)

Publication Number	Publication Date
NO975432D0 NO975432D0 (no)	1997-11-26
NO975432L NO975432L (no)	1997-11-26
NO317058B1 true NO317058B1 (no)	2004-08-02

Family

ID=26307190

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19975432A NO317058B1 (no)	1995-06-09	1997-11-26	Rapamycinderivater, fremgangsmate for fremstilling derav, farmasoytisk preparat omfattende et slikt derivat, kit omfattende et preparat samt anvendelse av derivatene

Country Status (29)

Country	Link
US (2)	US5985890A (pt)
EP (1)	EP0833828B1 (pt)
JP (1)	JP3226545B2 (pt)
KR (1)	KR100400620B1 (pt)
CN (1)	CN1124276C (pt)
AR (1)	AR003426A1 (pt)
AT (1)	ATE228135T1 (pt)
AU (1)	AU712193B2 (pt)
BR (1)	BR9609260A (pt)
CA (1)	CA2219659C (pt)
CO (1)	CO4440629A1 (pt)
CZ (1)	CZ292233B6 (pt)
DE (1)	DE69624921T2 (pt)
DK (1)	DK0833828T3 (pt)
ES (1)	ES2187660T3 (pt)
FI (1)	FI113051B (pt)
HU (1)	HU228234B1 (pt)
IL (1)	IL122212A (pt)
MY (1)	MY145291A (pt)
NO (1)	NO317058B1 (pt)
NZ (1)	NZ311647A (pt)
PE (1)	PE4598A1 (pt)
PL (1)	PL184731B1 (pt)
PT (1)	PT833828E (pt)
RU (1)	RU2158267C2 (pt)
SK (1)	SK284529B6 (pt)
TR (1)	TR199701567T1 (pt)
TW (1)	TW410226B (pt)
WO (1)	WO1996041807A1 (pt)

Families Citing this family (265)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0710110B1 (en)	1993-04-23	2002-03-06	Abbott Laboratories	Antibodies of ring opened rapamycins
US7279561B1 (en) *	1993-04-23	2007-10-09	Wyeth	Anti-rapamycin monoclonal antibodies
US6187757B1 (en) *	1995-06-07	2001-02-13	Ariad Pharmaceuticals, Inc.	Regulation of biological events using novel compounds
BE1009856A5 (fr)	1995-07-14	1997-10-07	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9606452D0 (en) *	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds
EP0937082A2 (en) *	1996-07-12	1999-08-25	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
US20050031611A1 (en) *	1998-05-08	2005-02-10	Beth Israel Deaconess Medical Center	Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
GB9826882D0 (en) *	1998-12-07	1999-01-27	Novartis Ag	Organic compounds
WO2000041698A1 (en)	1999-01-13	2000-07-20	Bayer Corporation	φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6955661B1 (en) *	1999-01-25	2005-10-18	Atrium Medical Corporation	Expandable fluoropolymer device for delivery of therapeutic agents and method of making
US6331547B1 (en)	1999-08-18	2001-12-18	American Home Products Corporation	Water soluble SDZ RAD esters
US7067526B1 (en)	1999-08-24	2006-06-27	Ariad Gene Therapeutics, Inc.	28-epirapalogs
EP1212331B1 (en)	1999-08-24	2004-04-21	Ariad Gene Therapeutics, Inc.	28-epirapalogs
US7807211B2 (en)	1999-09-03	2010-10-05	Advanced Cardiovascular Systems, Inc.	Thermal treatment of an implantable medical device
US6790228B2 (en)	1999-12-23	2004-09-14	Advanced Cardiovascular Systems, Inc.	Coating for implantable devices and a method of forming the same
US20070032853A1 (en)	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6277983B1 (en)	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
US7300662B2 (en)	2000-05-12	2007-11-27	Cordis Corporation	Drug/drug delivery systems for the prevention and treatment of vascular disease
US6670355B2 (en) *	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
US6399626B1 (en) *	2000-10-02	2002-06-04	Wyeth	Hydroxyesters of 7-desmethylrapamycin
US20040018228A1 (en) *	2000-11-06	2004-01-29	Afmedica, Inc.	Compositions and methods for reducing scar tissue formation
US6534693B2 (en)	2000-11-06	2003-03-18	Afmedica, Inc.	Surgically implanted devices having reduced scar tissue formation
US20040241211A9 (en) *	2000-11-06	2004-12-02	Fischell Robert E.	Devices and methods for reducing scar tissue formation
MXPA03004688A (es)	2000-11-28	2003-09-05	Wyeth Corp	Analisis de expresion de acidos nucleicos y polipeptidos fkbp utiles en diagnostico.
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
AU2011226835C1 (en) *	2001-02-19	2018-01-04	Novartis Ag	Cancer treatment
AU2005201004A1 (en) *	2001-02-19	2005-03-24	Novartis Ag	Cancer treatment
CN104083365A (zh) *	2001-02-19	2014-10-08	诺华股份有限公司	癌症的治疗
AU2016206379B2 (en) *	2001-02-19	2017-09-14	Novartis Ag	Cancer Treatment
CA2449019A1 (en) *	2001-05-29	2002-12-05	Guilford Pharmaceuticals Inc.	Method for treating nerve injury caused by surgery
ATE365557T1 (de) *	2001-08-13	2007-07-15	Fond Salvatore Maugeri Clinica	Verwendung von clarithromycin zur herstellung eines medikaments für die behandlung von arthrosis deformans
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
JP4547911B2 (ja) *	2002-02-01	2010-09-22	アリアド・ファーマシューティカルズ・インコーポレイテッド	リン含有化合物およびその用途
WO2003068228A1 (en)	2002-02-11	2003-08-21	Bayer Pharmaceuticals Corporation	Aryl ureas with angiogenesis inhibiting activity
EP1340498A1 (en) *	2002-03-01	2003-09-03	Schering Aktiengesellschaft	Use of epothilones in the treatment of brain diseases associated with proliferative processes
PT1505959E (pt)	2002-05-16	2009-02-05	Novartis Ag	Utilização de agentes de ligação do receptor edg em cancro
JP4265888B2 (ja) *	2002-06-12	2009-05-20	株式会社リコー	画像形成装置
WO2004007709A2 (en)	2002-07-16	2004-01-22	Biotica Technology Limited	Production of polyketides
TWI376363B (en)	2002-09-24	2012-11-11	Novartis Ag	Pharmaceutical combination for treating demyelinating disease
AU2003293529A1 (en)	2002-12-16	2004-07-29	Nitromed, Inc.	Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
ATE457716T1 (de)	2002-12-30	2010-03-15	Angiotech Int Ag	Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20070155771A1 (en) *	2003-04-11	2007-07-05	David Rubinsztein	Methods and means for treating protein conformational disorders
US7160867B2 (en)	2003-05-16	2007-01-09	Isotechnika, Inc.	Rapamycin carbohydrate derivatives
DE602004007382T2 (de)	2003-05-20	2008-04-17	Bayer Pharmaceuticals Corp., West Haven	Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
JP4351474B2 (ja) *	2003-06-05	2009-10-28	住友金属工業株式会社	ゴルフクラブヘッドフェース用板材の製造方法およびゴルフクラブヘッド
JP4041774B2 (ja) *	2003-06-05	2008-01-30	住友金属工業株式会社	β型チタン合金材の製造方法
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
CA2532251A1 (en) *	2003-07-25	2005-02-10	Wyeth	Cci-779 lyophilized formulations
CN1874771A (zh) *	2003-09-03	2006-12-06	惠氏公司	3－羟基－2－(羟甲基)－2－甲基丙酸的非晶态雷帕霉素42－酯及其包含相同化合物的药用组合物
US8021331B2 (en) *	2003-09-15	2011-09-20	Atrium Medical Corporation	Method of coating a folded medical device
US7659244B2 (en)	2003-11-03	2010-02-09	Quest Pharmatech, Inc.	Rapamycin peptides conjugates: synthesis and uses thereof
US7220755B2 (en) *	2003-11-12	2007-05-22	Biosensors International Group, Ltd.	42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
GB0327840D0 (en) *	2003-12-01	2003-12-31	Novartis Ag	Organic compounds
WO2006115509A2 (en)	2004-06-24	2006-11-02	Novartis Vaccines And Diagnostics Inc.	Small molecule immunopotentiators and assays for their detection
GB0417852D0 (en)	2004-08-11	2004-09-15	Biotica Tech Ltd	Production of polyketides and other natural products
US9000040B2 (en)	2004-09-28	2015-04-07	Atrium Medical Corporation	Cross-linked fatty acid-based biomaterials
US9012506B2 (en)	2004-09-28	2015-04-21	Atrium Medical Corporation	Cross-linked fatty acid-based biomaterials
US8795703B2 (en)	2004-09-28	2014-08-05	Atrium Medical Corporation	Stand-alone film and methods for making the same
US8021849B2 (en) *	2004-11-05	2011-09-20	Siemens Healthcare Diagnostics Inc.	Methods and kits for the determination of sirolimus in a sample
WO2006053754A1 (en) *	2004-11-19	2006-05-26	Novartis Ag	COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
HN2005035605A (es) *	2004-12-20	2010-08-05	Wyeth Corp	Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
GB0504544D0 (en)	2005-03-04	2005-04-13	Novartis Ag	Organic compounds
KR20070116868A (ko)	2005-03-11	2007-12-11	바이오티카 테크놀로지 리미티드	３９데스메톡시라파마이신 및 그 유사체의 의학적 용도
GB0504994D0 (en)	2005-03-11	2005-04-20	Biotica Tech Ltd	Novel compounds
US7189582B2 (en) *	2005-04-27	2007-03-13	Dade Behring Inc.	Compositions and methods for detection of sirolimus
BRPI0611021A2 (pt) *	2005-05-31	2010-08-10	Novartis Ag	combinação de inibidores de hmg-coa redutase e inibidores de mtor
CA2615452C (en)	2005-07-15	2015-03-31	Micell Technologies, Inc.	Polymer coatings containing drug powder of controlled morphology
US20090062909A1 (en)	2005-07-15	2009-03-05	Micell Technologies, Inc.	Stent with polymer coating containing amorphous rapamycin
RU2443418C2 (ru)	2005-07-20	2012-02-27	Новартис Аг	КОМБИНАЦИЯ ПИРИМИДИЛАМИНОБЕНЗАМИДА И ИНГИБИТОРА КИНАЗ mTOR
UA97469C2 (uk)	2005-07-25	2012-02-27	Емерджент Продакт Дівелопмент Сіетл, Елелсі	Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
JP5164167B2 (ja)	2005-08-30	2013-03-13	ユニバーシティーオブマイアミ	免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
US9427423B2 (en)	2009-03-10	2016-08-30	Atrium Medical Corporation	Fatty-acid based particles
US9278161B2 (en)	2005-09-28	2016-03-08	Atrium Medical Corporation	Tissue-separating fatty acid adhesion barrier
US20070134739A1 (en) *	2005-12-12	2007-06-14	Gyros Patent Ab	Microfluidic assays and microfluidic devices
GB0601406D0 (en) *	2006-01-24	2006-03-08	Novartis Ag	Organic Compounds
EP3348265A1 (en) *	2006-02-02	2018-07-18	Novartis AG	Tuberous sclerosis treatment
WO2007127363A2 (en)	2006-04-26	2007-11-08	Micell Technologies, Inc.	Coatings containing multiple drugs
JP2010501499A (ja) *	2006-08-22	2010-01-21	ノバルティスアクチエンゲゼルシャフト	線維症の処置
US10695327B2 (en)	2006-09-13	2020-06-30	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
US7867988B2 (en)	2006-09-13	2011-01-11	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
US8088789B2 (en)	2006-09-13	2012-01-03	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
WO2008065887A1 (en) *	2006-11-27	2008-06-05	Terumo Kabushiki Kaisha	Process for producing o-alkylated rapamycin derivative, and o-alkylated rapamycin derivative
US11426494B2 (en)	2007-01-08	2022-08-30	MT Acquisition Holdings LLC	Stents having biodegradable layers
CA2679712C (en)	2007-01-08	2016-11-15	Micell Technologies, Inc.	Stents having biodegradable layers
US7938286B2 (en) *	2007-02-13	2011-05-10	Gateway Plastics, Inc.	Container system
US8921642B2 (en)	2008-01-11	2014-12-30	Massachusetts Eye And Ear Infirmary	Conditional-stop dimerizable caspase transgenic animals
US20100048524A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20090253733A1 (en) *	2008-04-02	2009-10-08	Biointeractions, Ltd.	Rapamycin carbonate esters
NZ621443A (en)	2008-04-11	2015-09-25	Emergent Product Dev Seattle	Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CN102083397B (zh)	2008-04-17	2013-12-25	米歇尔技术公司	具有生物可吸收层的支架
KR20110020928A (ko)	2008-06-20	2011-03-03	노파르티스 아게	다발성 경화증을 치료하기 위한 소아용 조성물
CA2730995C (en)	2008-07-17	2016-11-22	Micell Technologies, Inc.	Drug delivery medical device
JP2012504654A (ja) *	2008-10-03	2012-02-23	エリクシアーメディカルコーポレイション	多環状ラクトン化合物およびその使用方法
CN102292078A (zh)	2008-11-11	2011-12-21	得克萨斯大学体系董事会	哺乳动物雷帕霉素靶蛋白的抑制
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
BRPI1008745A2 (pt)	2009-02-05	2019-09-17	Tokai Pharmaceuticals Inc	pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
JP2012522589A (ja)	2009-04-01	2012-09-27	ミシェルテクノロジーズ，インコーポレイテッド	被覆ステント
EP3366326A1 (en)	2009-04-17	2018-08-29	Micell Technologies, Inc.	Stents having controlled elution
EP2453834A4 (en)	2009-07-16	2014-04-16	Micell Technologies Inc	MEDICAL DEVICE DISPENSING MEDICINE
AU2010279637B2 (en)	2009-08-03	2012-08-23	University Of Miami	Method for in vivo expansion of T regulatory cells
US20110038910A1 (en)	2009-08-11	2011-02-17	Atrium Medical Corporation	Anti-infective antimicrobial-containing biomaterials
US20170079962A1 (en)	2009-11-11	2017-03-23	Rapamycin Holdings, Llc	Oral Rapamycin Preparation and Use for Stomatitus
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
EP2531140B1 (en)	2010-02-02	2017-11-01	Micell Technologies, Inc.	Stent and stent delivery system with improved deliverability
JP5918214B2 (ja)	2010-04-13	2016-05-18	ノバルティスアーゲー	がんを治療するためのサイクリン依存性キナーゼ４またはサイクリン依存性キナーゼ（ｃｄｋ４／６）阻害剤およびｍｔｏｒ阻害剤を含む組合せ
PH12012501977A1 (en)	2010-04-16	2013-01-07	Novartis Ag	Combination of organic compounds
US10232092B2 (en)	2010-04-22	2019-03-19	Micell Technologies, Inc.	Stents and other devices having extracellular matrix coating
CN102844049B (zh)	2010-04-27	2016-06-01	罗切格利卡特公司	无岩藻糖基化CD20抗体与mTOR抑制剂的联合疗法
EP2593039B1 (en)	2010-07-16	2022-11-30	Micell Technologies, Inc.	Drug delivery medical device
EP2593141B1 (en)	2010-07-16	2018-07-04	Atrium Medical Corporation	Composition and methods for altering the rate of hydrolysis of cured oil-based materials
KR102024948B1 (ko)	2011-02-18	2019-11-04	노파르티스 파르마 아게	mTOR/JAK 저해제 병용 요법
SG193919A1 (en)	2011-04-25	2013-11-29	Novartis Ag	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US10117972B2 (en)	2011-07-15	2018-11-06	Micell Technologies, Inc.	Drug delivery medical device
US10188772B2 (en)	2011-10-18	2019-01-29	Micell Technologies, Inc.	Drug delivery medical device
EP2589383A1 (en)	2011-11-06	2013-05-08	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin	FKBP subtype-specific rapamycin analogue for use in treatment of diseases
WO2013072392A1 (en)	2011-11-15	2013-05-23	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway
GB201122305D0 (en)	2011-12-23	2012-02-01	Biotica Tech Ltd	Novel compound
US9867880B2 (en)	2012-06-13	2018-01-16	Atrium Medical Corporation	Cured oil-hydrogel biomaterial compositions for controlled drug delivery
WO2013192367A1 (en)	2012-06-22	2013-12-27	Novartis Ag	Neuroendocrine tumor treatment
EP2869818A1 (en)	2012-07-06	2015-05-13	Novartis AG	Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
WO2014059295A1 (en)	2012-10-12	2014-04-17	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors to treat vascular cognitive impairment
EP2919759A4 (en)	2012-11-14	2016-07-20	Ohio State Innovation Foundation	MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
AU2014205366B2 (en)	2013-01-09	2018-12-20	Eckhard R. Podack	Compositions and methods for the regulation of T regulatory cells using Tl1a-Ig fusion protein
CA2905419C (en)	2013-03-12	2020-04-28	Micell Technologies, Inc.	Bioabsorbable biomedical implants
US20160030401A1 (en)	2013-03-13	2016-02-04	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
EP4066841A1 (en)	2013-03-14	2022-10-05	University of Maryland, Baltimore	Androgen receptor down-regulating agents and uses thereof
EP2994758B1 (en)	2013-05-08	2017-12-20	Opthea Limited	Biomarkers for age-related macular degeneration (amd)
KR102079613B1 (ko)	2013-05-15	2020-02-20	미셀 테크놀로지즈, 인코포레이티드	생흡수성 생체의학적 임플란트
US9593356B2 (en)	2013-06-11	2017-03-14	Takara Bio Usa, Inc.	Protein enriched microvesicles and methods of making and using the same
CA2911104A1 (en) *	2013-06-20	2014-12-24	Novartis Ag	Alkylation with an alkyl fluoroalkyl sulfonate
WO2015023710A1 (en)	2013-08-12	2015-02-19	Tokai Pharmaceuticals, Inc.	Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US9580758B2 (en)	2013-11-12	2017-02-28	Luc Montagnier	System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
TWI679976B (zh)	2013-11-13	2019-12-21	瑞士商諾華公司	低及免疫增強劑量之ｍｔｏｒ抑制劑及其用途
BR112016013187A2 (pt)	2013-12-19	2017-09-26	Novartis Ag	receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
US10287354B2 (en)	2013-12-20	2019-05-14	Novartis Ag	Regulatable chimeric antigen receptor
CN103739616B (zh) *	2013-12-27	2015-12-30	福建省微生物研究所	含噻唑基雷帕霉素类衍生物及其应用
CA3206208A1 (en)	2013-12-31	2015-07-09	Rapamycin Holdings, Llc	Oral rapamycin nanoparticle preparations and use
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
US20170165246A1 (en)	2014-02-11	2017-06-15	Novartis Ag	Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
US20170081411A1 (en)	2014-03-15	2017-03-23	Novartis Ag	Regulatable chimeric antigen receptor
WO2015142675A2 (en)	2014-03-15	2015-09-24	Novartis Ag	Treatment of cancer using chimeric antigen receptor
CA2943609A1 (en)	2014-03-27	2015-10-01	The Brigham And Women's Hospital, Inc.	Metabolically-activated drug conjugates to overcome resistance in cancer therapy
MX395149B (es)	2014-04-07	2025-03-24	Novartis Ag	Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer.
WO2015171723A1 (en)	2014-05-06	2015-11-12	Research Development Foundation	Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
KR20170031668A (ko)	2014-06-02	2017-03-21	칠드런'즈 메디컬 센터 코포레이션	면역 조절을 위한 방법 및 조성물
US9777061B2 (en)	2014-07-21	2017-10-03	Novartis Ag	Treatment of cancer using a CD33 chimeric antigen receptor
WO2016014530A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016014553A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Sortase synthesized chimeric antigen receptors
US20170209492A1 (en)	2014-07-31	2017-07-27	Novartis Ag	Subset-optimized chimeric antigen receptor-containing t-cells
JP6919118B2 (ja)	2014-08-14	2021-08-18	ノバルティスアーゲー	ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
TW202140557A (zh)	2014-08-19	2021-11-01	瑞士商諾華公司	使用cd123嵌合抗原受體治療癌症
WO2016040806A1 (en)	2014-09-11	2016-03-17	The Regents Of The University Of California	mTORC1 INHIBITORS
KR20210149228A (ko)	2014-09-17	2021-12-08	노파르티스 아게	입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
CA2963935A1 (en)	2014-10-08	2016-04-14	Novartis Ag	Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016066608A1 (en)	2014-10-28	2016-05-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
WO2016164580A1 (en)	2015-04-07	2016-10-13	Novartis Ag	Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CA2982996A1 (en)	2015-04-17	2016-10-20	David Maxwell Barrett	Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en)	2015-04-23	2016-10-27	Novartis Ag	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
AU2016263176A1 (en)	2015-05-20	2017-12-07	Novartis Ag	Pharmaceutical combination of everolimus with dactolisib
KR102764084B1 (ko)	2015-11-11	2025-02-07	노파르티스 아게	미오스타틴 길항제의 용도, 이들을 함유하는 조합물 및 그의 용도
CA3021645A1 (en)	2016-04-29	2017-11-02	Icahn School Of Medicine At Mount Sinai	Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
WO2018017708A1 (en)	2016-07-20	2018-01-25	University Of Utah Research Foundation	Cd229 car t cells and methods of use thereof
CN110225927B (zh)	2016-10-07	2024-01-12	诺华股份有限公司	用于治疗癌症的嵌合抗原受体
CA3044355A1 (en)	2016-11-23	2018-05-31	Novartis Ag	Methods of enhancing immune response with everolimus, dactolisib or both
WO2018100190A1 (en)	2016-12-02	2018-06-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for diagnosing renal cell carcinoma
SG11201906223TA (en)	2016-12-22	2019-08-27	Amgen Inc	Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
US20200131196A1 (en)	2017-02-10	2020-04-30	Mount Tam Therapeutics, Inc.	Rapamycin Analog
EP3615055A1 (en)	2017-04-28	2020-03-04	Novartis AG	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20210154372A1 (en)	2017-05-15	2021-05-27	C.R. Bard, Inc.	Medical device with drug-eluting coating and intermediate layer
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
UY37870A (es)	2017-09-08	2019-03-29	Amgen Inc	Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
UY37900A (es) *	2017-09-26	2019-04-30	Novartis Ag	Nuevos derivados de rapamicina
US10596165B2 (en)	2018-02-12	2020-03-24	resTORbio, Inc.	Combination therapies
EP3784351A1 (en)	2018-04-27	2021-03-03	Novartis AG	Car t cell therapies with enhanced efficacy
US20210396739A1 (en)	2018-05-01	2021-12-23	Novartis Ag	Biomarkers for evaluating car-t cells to predict clinical outcome
MX2020011564A (es)	2018-05-01	2021-01-29	Revolution Medicines Inc	Analogos de rapamicina unidos a c26 como inhibidores de mtor.
PE20252397A1 (es)	2018-05-01	2025-10-10	Revolution Medicines Inc	Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor
MA52501A (fr)	2018-05-04	2021-03-10	Amgen Inc	Inhibiteurs de kras g12c et leurs procédés d'utilisation
CA3099118A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
MX2020011907A (es)	2018-05-10	2021-01-29	Amgen Inc	Inhibidores de kras g12c para el tratamiento de cancer.
AU2019278998B2 (en)	2018-06-01	2023-11-09	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
JP7357644B2 (ja)	2018-06-11	2023-10-06	アムジエン・インコーポレーテツド	がんを処置するためのｋｒａｓｇ１２ｃ阻害剤
AU2019336588B2 (en)	2018-06-12	2022-07-28	Amgen Inc.	KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
SI3813946T1 (sl)	2018-06-15	2024-07-31	Janssen Pharmaceutica Nv	Analogi rapamicina in njihove uporabe
CN113226389B (zh)	2018-11-14	2022-11-08	乐通公司	在经改性设备表面上具有药物洗脱涂层的医疗设备
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020106640A1 (en)	2018-11-19	2020-05-28	Amgen Inc.	Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020128861A1 (en)	2018-12-18	2020-06-25	Novartis Ag	Rapamycin derivatives
ES2996960T3 (en)	2018-12-20	2025-02-13	Amgen Inc	Heteroaryl amides useful as kif18a inhibitors
EP3897855B1 (en)	2018-12-20	2023-06-07	Amgen Inc.	Kif18a inhibitors
JOP20210154B1 (ar)	2018-12-20	2023-09-17	Amgen Inc	مثبطات kif18a
US12441736B2 (en)	2018-12-20	2025-10-14	Amgen Inc.	KIF18A inhibitors
US20230148450A9 (en)	2019-03-01	2023-05-11	Revolution Medicines, Inc.	Bicyclic heteroaryl compounds and uses thereof
WO2020180770A1 (en)	2019-03-01	2020-09-10	Revolution Medicines, Inc.	Bicyclic heterocyclyl compounds and uses thereof
WO2020209828A1 (en)	2019-04-08	2020-10-15	Bard Peripheral Vascular, Inc.	Medical device with drug-eluting coating on modified device surface
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
CR20210665A (es)	2019-05-21	2022-01-25	Amgen Inc	Formas en estado sólido
TW202114681A (zh)	2019-07-02	2021-04-16	美商ｅＦＦＥＣＴＯＲ醫療公司	轉譯抑制劑及其用途
CN114302880B (zh)	2019-08-02	2025-07-15	美国安进公司	Kif18a抑制剂
WO2021026099A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
US20220281843A1 (en)	2019-08-02	2022-09-08	Amgen Inc.	Kif18a inhibitors
CN114391012B (zh)	2019-08-02	2025-10-31	美国安进公司	作为kif18a抑制剂的吡啶衍生物
BR112022003490A2 (pt)	2019-08-26	2022-05-24	Arvinas Operations Inc	Método de tratamento do câncer de mama e mama metastático, método para degradação seletiva, método para inibir uma quinase, kit, composição líquida, e, método de produção de uma composição líquida
WO2021055728A1 (en)	2019-09-18	2021-03-25	Merck Sharp & Dohme Corp.	Small molecule inhibitors of kras g12c mutant
TW202126323A (zh) *	2019-10-01	2021-07-16	約翰斯赫普金斯大學	雷帕弗辛（Ｒａｐａｆｕｃｉｎ）衍生化合物及其使用方法
EP4684786A2 (en)	2019-10-24	2026-01-28	Amgen Inc.	Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
CR20220230A (es)	2019-10-28	2022-06-15	Merck Sharp & Dohme	Inhibidores de pequeñas moléculas de mutante g12c de kras
CN119424423A (zh)	2019-10-31	2025-02-14	大鹏药品工业株式会社	4-氨基丁-2-烯酰胺衍生物及其盐
US11739074B2 (en)	2019-11-04	2023-08-29	Revolution Medicines, Inc.	Ras inhibitors
CN120988055A (zh)	2019-11-04	2025-11-21	锐新医药公司	Ras抑制剂
CA3160142A1 (en)	2019-11-04	2021-05-14	Revolution Medicines, Inc.	Ras inhibitors
JP7812056B2 (ja)	2019-11-08	2026-02-09	レヴォリューション・メディスンズ，インコーポレイテッド	二環式ヘテロアリール化合物及びその使用
AU2020383535A1 (en)	2019-11-14	2022-05-05	Amgen Inc.	Improved synthesis of KRAS G12C inhibitor compound
TWI882037B (zh)	2019-11-14	2025-05-01	美商安進公司	Kras g12c抑制劑化合物之改善的合成
CN114980976A (zh)	2019-11-27	2022-08-30	锐新医药公司	共价ras抑制剂及其用途
WO2021106231A1 (en)	2019-11-29	2021-06-03	Taiho Pharmaceutical Co., Ltd.	A compound having inhibitory activity against kras g12d mutation
BR112022010754A2 (pt)	2019-12-05	2022-08-23	Anakuria Therapeutics Inc	Análogos de rapamicina e usos dos mesmos
EP4073102A4 (en)	2019-12-12	2024-05-08	Ting Therapeutics LLC	Compositions and methods for the prevention and treatment of hearing loss
BR112022010086A2 (pt)	2020-01-07	2022-09-06	Revolution Medicines Inc	Dosagem do inibidor de shp2 e métodos de tratamento de câncer
US20230174518A1 (en)	2020-04-24	2023-06-08	Taiho Pharmaceutical Co., Ltd.	Kras g12d protein inhibitors
US20230181536A1 (en)	2020-04-24	2023-06-15	Taiho Pharmaceutical Co., Ltd.	Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
TW202216151A (zh)	2020-07-15	2022-05-01	日商大鵬藥品工業股份有限公司	含有使用於腫瘤之治療之嘧啶化合物之組合
AU2021344830A1 (en)	2020-09-03	2023-04-06	Revolution Medicines, Inc.	Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
MX2023003060A (es)	2020-09-15	2023-04-05	Revolution Medicines Inc	Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
EP4267250A1 (en)	2020-12-22	2023-11-01	Qilu Regor Therapeutics Inc.	Sos1 inhibitors and uses thereof
WO2022198101A1 (en)	2021-03-19	2022-09-22	Trained Therapeutix Discovery, Inc.	Compounds for regulating trained immunity, and their methods of use
TW202309053A (zh)	2021-05-05	2023-03-01	美商銳新醫藥公司	Ｒａｓ抑制劑
WO2022235866A1 (en)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
IL308193A (en)	2021-05-05	2024-01-01	Revolution Medicines Inc	RAS inhibitors
JP2024521979A (ja)	2021-05-28	2024-06-04	大鵬薬品工業株式会社	Ｋｒａｓ変異タンパク質の小分子阻害剤関連出願の相互参照
WO2023288046A1 (en)	2021-07-15	2023-01-19	President And Fellows Of Harvard College	Compositions and methods relating to cells with adhered particles
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
WO2023064058A1 (en)	2021-10-12	2023-04-20	Peloton Therapeutics Inc.	Tricyclic sultams and sulfamides as antitumor agents
US20250282782A1 (en)	2021-12-17	2025-09-11	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
EP4490146B1 (en)	2022-03-07	2026-02-18	Amgen Inc.	A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
CN119136806A (zh)	2022-03-08	2024-12-13	锐新医药公司	用于治疗免疫难治性肺癌的方法
EP4531859A1 (en)	2022-05-25	2025-04-09	Revolution Medicines, Inc.	Methods of treating cancer with an mtor inhibitor
JP2025521232A (ja)	2022-06-10	2025-07-08	レボリューションメディシンズインコーポレイテッド	大環状ｒａｓ阻害剤
GEAP202516749A (en)	2022-10-14	2025-07-25	Black Diamond Therapeutics Inc	Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024167904A1 (en)	2023-02-07	2024-08-15	Arvinas Operations, Inc.	Dosage regimens of estrogen receptor degraders in combination with an mtor inhibitor
EP4687905A1 (en)	2023-03-30	2026-02-11	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
EP4688790A1 (en)	2023-04-07	2026-02-11	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
WO2024211738A1 (en)	2023-04-07	2024-10-10	Regeneron Pharmaceuticals, Inc.	Selective rapamycin analogs and uses thereof
WO2024211663A1 (en)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Condensed macrocyclic compounds as ras inhibitors
KR20250169290A (ko)	2023-04-14	2025-12-02	레볼루션 메디슨즈, 인크.	Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법
KR20250172857A (ko)	2023-04-14	2025-12-09	레볼루션 메디슨즈, 인크.	Ras 억제제의 결정형
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
WO2025034702A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025043187A1 (en)	2023-08-24	2025-02-27	Otsuka Pharmaceutical Co., Ltd.	Fixed dose combinations of cedazuridine and azacitidine
US20250154171A1 (en)	2023-10-12	2025-05-15	Revolution Medicines, Inc.	Ras inhibitors
TW202535891A (zh)	2023-10-20	2025-09-16	美商默沙東有限責任公司	Ｋｒａｓ蛋白之小分子抑制劑
WO2025137507A1 (en)	2023-12-22	2025-06-26	Regor Pharmaceuticals, Inc.	Sos1 inhibitors and uses thereof
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
WO2025255438A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5221670A (en) *	1990-09-19	1993-06-22	American Home Products Corporation	Rapamycin esters
PT98990A (pt) *	1990-09-19	1992-08-31	American Home Prod	Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en) *	1991-04-01	1992-06-09	American Home Products Corporation	Silyl ethers of rapamycin
US5100883A (en) *	1991-04-08	1992-03-31	American Home Products Corporation	Fluorinated esters of rapamycin
US5118678A (en) *	1991-04-17	1992-06-02	American Home Products Corporation	Carbamates of rapamycin
US5118677A (en) *	1991-05-20	1992-06-02	American Home Products Corporation	Amide esters of rapamycin
US5151413A (en) *	1991-11-06	1992-09-29	American Home Products Corporation	Rapamycin acetals as immunosuppressant and antifungal agents
US5516781A (en)	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
CA2086642C (en)	1992-01-09	2004-06-15	Randall E. Morris	Method of treating hyperproliferative vascular disease
KR100284210B1 (ko)	1992-04-28	2001-03-02	이건 이. 버그	과증식성 혈관 질환 치료용 배합 제제
ZA935112B (en) *	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
US5256790A (en) *	1992-08-13	1993-10-26	American Home Products Corporation	27-hydroxyrapamycin and derivatives thereof
MX9304868A (es) *	1992-08-13	1994-05-31	American Home Prod	27-hidroxirapamicina, derivados de la misma y composicion farmaceutica que la contiene.
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5262423A (en) *	1992-10-29	1993-11-16	American Home Products Corporation	Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) *	1992-11-09	1993-11-02	Merck & Co., Inc.	O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5310903A (en) *	1993-03-05	1994-05-10	Merck & Co., Inc.	Imidazolidyl rapamycin derivatives
US5310901A (en) *	1993-03-05	1994-05-10	Merck & Co., Inc.	O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
US5387680A (en) *	1993-08-10	1995-02-07	American Home Products Corporation	C-22 ring stabilized rapamycin derivatives
US5527907A (en) *	1993-11-19	1996-06-18	Abbott Laboratories	Macrolide immunomodulators
WO1995014023A1 (en) *	1993-11-19	1995-05-26	Abbott Laboratories	Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
HUT74686A (en)	1993-12-17	1997-01-28	Sandoz Ag	Rapamycin derivatives, their pharmaceutical use, process for producing them and pharmaceutical composition containing them as active agents

1996
- 1996-06-05 ES ES96921931T patent/ES2187660T3/es not_active Expired - Lifetime
- 1996-06-05 CN CN96194681A patent/CN1124276C/zh not_active Expired - Lifetime
- 1996-06-05 DE DE69624921T patent/DE69624921T2/de not_active Expired - Lifetime
- 1996-06-05 AT AT96921931T patent/ATE228135T1/de active
- 1996-06-05 TR TR97/01567T patent/TR199701567T1/xx unknown
- 1996-06-05 DK DK96921931T patent/DK0833828T3/da active
- 1996-06-05 EP EP96921931A patent/EP0833828B1/en not_active Expired - Lifetime
- 1996-06-05 IL IL12221296A patent/IL122212A/xx not_active IP Right Cessation
- 1996-06-05 KR KR1019970709247A patent/KR100400620B1/ko not_active Expired - Fee Related
- 1996-06-05 JP JP50258797A patent/JP3226545B2/ja not_active Expired - Fee Related
- 1996-06-05 US US08/973,604 patent/US5985890A/en not_active Expired - Lifetime
- 1996-06-05 PL PL96323310A patent/PL184731B1/pl unknown
- 1996-06-05 RU RU98100481/04A patent/RU2158267C2/ru active
- 1996-06-05 NZ NZ311647A patent/NZ311647A/xx not_active IP Right Cessation
- 1996-06-05 SK SK1682-97A patent/SK284529B6/sk not_active IP Right Cessation
- 1996-06-05 CA CA002219659A patent/CA2219659C/en not_active Expired - Lifetime
- 1996-06-05 BR BR9609260A patent/BR9609260A/pt not_active Application Discontinuation
- 1996-06-05 WO PCT/EP1996/002441 patent/WO1996041807A1/en not_active Ceased
- 1996-06-05 AU AU63006/96A patent/AU712193B2/en not_active Expired
- 1996-06-05 CZ CZ19973922A patent/CZ292233B6/cs not_active IP Right Cessation
- 1996-06-05 HU HU9802200A patent/HU228234B1/hu unknown
- 1996-06-05 PT PT96921931T patent/PT833828E/pt unknown
- 1996-06-06 AR ARP960102978A patent/AR003426A1/es active IP Right Grant
- 1996-06-06 MY MYPI96002232A patent/MY145291A/en unknown
- 1996-06-07 PE PE1996000444A patent/PE4598A1/es not_active IP Right Cessation
- 1996-06-07 CO CO96029756A patent/CO4440629A1/es unknown
- 1996-06-07 TW TW085106847A patent/TW410226B/zh not_active IP Right Cessation
1997
- 1997-10-17 FI FI973991A patent/FI113051B/fi not_active IP Right Cessation
- 1997-11-26 NO NO19975432A patent/NO317058B1/no not_active IP Right Cessation
1999
- 1999-07-19 US US09/356,587 patent/US6200985B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
FI973991A0 (fi)	1997-10-17
KR100400620B1 (ko)	2004-02-18
HUP9802200A2 (hu)	1999-02-01
AU6300696A (en)	1997-01-09
FI973991L (fi)	1997-12-09
CZ392297A3 (cs)	1998-03-18
RU2158267C2 (ru)	2000-10-27
DE69624921D1 (de)	2003-01-02
HK1014949A1 (en)	1999-10-08
SK284529B6 (sk)	2005-05-05
IL122212A (en)	2001-08-26
HUP9802200A3 (en)	2000-05-29
CZ292233B6 (cs)	2003-08-13
FI113051B (fi)	2004-02-27
IL122212A0 (en)	1998-04-05
BR9609260A (pt)	1999-05-18
US6200985B1 (en)	2001-03-13
TW410226B (en)	2000-11-01
PE4598A1 (es)	1998-02-19
DK0833828T3 (da)	2003-03-17
CA2219659C (en)	2008-03-18
ATE228135T1 (de)	2002-12-15
AR003426A1 (es)	1998-08-05
NO975432D0 (no)	1997-11-26
AU712193B2 (en)	1999-10-28
EP0833828A1 (en)	1998-04-08
US5985890A (en)	1999-11-16
CN1187821A (zh)	1998-07-15
NO975432L (no)	1997-11-26
TR199701567T1 (xx)	1998-04-21
NZ311647A (en)	1999-11-29
CN1124276C (zh)	2003-10-15
PT833828E (pt)	2003-02-28
JP3226545B2 (ja)	2001-11-05
MX9709555A (es)	1998-03-31
EP0833828B1 (en)	2002-11-20
ES2187660T3 (es)	2003-06-16
CA2219659A1 (en)	1996-12-27
HU228234B1 (en)	2013-02-28
CO4440629A1 (es)	1997-05-07
SK168297A3 (en)	1998-05-06
KR19990022780A (ko)	1999-03-25
MY145291A (en)	2012-01-13
PL323310A1 (en)	1998-03-16
WO1996041807A1 (en)	1996-12-27
JP2000510815A (ja)	2000-08-22
DE69624921T2 (de)	2003-09-11
PL184731B1 (pl)	2002-12-31

Publication	Publication Date	Title
NO317058B1 (no)	2004-08-02	Rapamycinderivater, fremgangsmate for fremstilling derav, farmasoytisk preparat omfattende et slikt derivat, kit omfattende et preparat samt anvendelse av derivatene
AU676198B2 (en)	1997-03-06	O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
EP0734389B1 (en)	2000-03-29	Rapamycin derivatives useful as immunosuppressants
JPH0578377A (ja)	1993-03-30	ラパマイシンのシリルエーテル類
MXPA97009555A (en)	1998-10-15	Derivatives of rapamic
HK1014949B (en)	2004-07-09	Rapamycin derivatives
CA2174731C (en)	2006-10-31	Rapamycin derivatives useful as immunosuppressants

Legal Events

Date	Code	Title	Description
2016-01-25	MM1K	Lapsed by not paying the annual fees